Insights & Resources

Is your transaction a business combination or asset acquisition? Learn how ASC 805 guidance, the screen test and key differences shape reporting.

Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.

Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.

Health care providers face rising risks in privacy, AI and HIPAA enforcement. Find out what hospitals can do now to strengthen compliance efforts.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Artificial intelligence (AI) is reshaping security, from threat detection to risk management. Explore the top three security measures for effective AI integration.

Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.

Learn how financial institutions can manage third-party risks, protect customer trust and minimize disruptions from critical service outages.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.